Evaluation of Hepatocyte Growth Factor in Iraqi Patients with Acute Myeloid Leukemia: Its Correlation with Clinical Parameters and Response to Induction Therapy
its correlation with clinical parameters and response to induction therapy
DOI:
https://doi.org/10.3889/oamjms.2020.4235Keywords:
Acute myeloid leukemia, Hepatocyte growth factor, Remission inductionAbstract
BACKGROUND: Hepatocyte growth factor (HGF) is a proangiogenic factor that exerts different effects over stem cell survival growth, apoptosis, and adhesion. Its impact on leukemogenesis has been established by many studies.
AIM: This study aimed to determine the effect of plasma HGF activity on acute myeloid leukemia (AML) patients at presentation and after remission.
PATIENTS AND METHODS: This was a cross-sectional prospective study of 30 newly-diagnosed, adult, and AML patients. All patients received the 7+3 treatment protocol. Patients’ clinical data were taken at presentation, and patients were followed up for 6 months to evaluate the clinical status. Plasma HGF levels were estimated by ELISA based methods in the patients at two intervals first at diagnosis and the 2nd time after remission of disease. Plasma HGF levels were only measured once in twenty healthy control individuals.
RESULTS: A statistically significant lowering in the median levels of HGF after remission induction therapy has been found when compared with those before treatment (p = 0.006) and in the group of patients who achieved complete remission in comparison with those before treatment (p = 0.005). Furthermore, a significant reduction was also demonstrated after treatment in patients presenting with extramedullary involvement (p = 0.003) and in the alive group (p = 0.001).
CONCLUSION: Plasma HGF estimation can be a useful parameter in predicting treatment outcomes in patients with AML, and it can add potentially useful information to risk stratification parameters.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Saultz JN, Garzon R. Acute myeloid leukemia: A concise review. J Clin Med. 2016;5(3):e33. PMid:26959069
Obeyed HH, Ibrahim RH, Ali KM, Abdo-Alkareem, Hasan AH, Nasser LM, et al. Annual Report Iraqi Cancer Registry 2016. Baghdad: Iraqi Cancer Board; 2018. Available from: https://moh. gov.iq/upload/upfile/ar/882.pdf
Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87. https://doi.org/10.1016/j. blre.2019.04.005 PMid:31101526
Burnett AK, Grimwade D. Acute myeloid leukaemia. In: Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB, editorss. Postgraduate Haematology. 7th ed. Chichester, UK: Wiley Blackwell; 2016. p. 352-69. https://doi.org/10.1002/9781118853771.ch20
Ossenkoppele G, Montesinos P. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;138:6-13. PMid:31092386
De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: A comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. https://doi.org/10.1038/bcj.2016.50 PMid:27367478
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-52. PMid:26376137
Haouas H. Angiogenesis and acute myeloid leukemia. Hematology 2014;19(6):311-23. PMid:24192539
Haouas H. Angiogenesis in hematological malignancy-evaluated by dynamic contrast-enhanced MRI. J Cancer Res Pract. 2016;3(4):97-103.
Reikvam H, Hatfield KJ, Fredly H, Nepstad I, Mosevoll KA, Bruserud Ø. The angioregulatory cytokine network in human acute myeloid leukemia from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw. 2012;23(4):140-53. https://doi.org/10.1684/ecn.2012.0322 PMid:23328436
Roversi FM, Cury NM, Lopes MR, Ferro KP, Machado- Neto JA, Alvarez MC, et al. Up-regulation of SPINT2/HAI-2 by azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion. J Cell Mol Med. 2019;23(2):1562-71. https://doi.org/10.1111/jcmm.14066 PMid:30484958
Guo JR, Li W, Wu Y, Wu LQ, Li X, Guo YF, et al. Hepatocyte growth factor promotes proliferation, invasion, and metastasis of myeloid leukemia cells through PI3K-AKT and MAPK/ERK signaling pathway. Am J Transl Res. 2016;8(9):3630-44. PMid:27725846
Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 1999;29(3):209- 48. https://doi.org/10.1016/s1040-8428(98)00019-5 PMid:10226727
Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47. https://doi.org/10.1182/ blood-2016-08-733196 PMid:27895058
Quantikine® ELISA Human HGF Immunoassay Kit (Catalog Number DHG00), R&D Systems, Inc., 614 McKinley Place NE, Minneapolis, MN 55413, USA. Available from: https://www. rndsystems.com/products/human-hgf-quantikine-elisa-kit_ dhg00#product-datasheets. [Last accessed on 2017 Mar 23].
Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637-44. https://doi. org/10.1182/blood.v95.8.2637 PMid:10753845
Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93(9):3064-73. https://doi.org/10.1182/blood.v93.9.3064 PMid:10216103
Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815-21. PMid:9060819
Ahmed AE, El-Baser KA, Zytoun SS, Alsenbesy MA, Elsaid AE. Estimation of plasma concentrations of hepatocyte growth factor in acute leukemia in Upper Egypt. Egypt Pediatr Assoc Gaz. 2015;63(1):12-8. https://doi.org/10.4103/1110-1067.155789
Hjorth-Hansen H, Seidel C, Lamvik J, Börset M, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Eur J Haematol. 1999;62(2):129-34. https://doi.org/10.1111/j.1600-0609.1999. tb01733.x PMid:10052717
Aref S, Mabed M, Sakrana M, Goda T, El-Sherbiny M. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: Relationship to disease characteristics. Hematology. 2002;7(5):273-9. https:// doi.org/10.1080/1024533021000037207 PMid:12850814
Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 2005;46(6):885-91. https://doi. org/10.1080/10428190500054491 PMid:16019534
Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001;15(8):1165-70. https://doi.org/10.1038/sj.leu.2402182 PMid:11480557
Sakon M, Kita Y, Takeda Y, Higaki N, Ohzato H, Umeshita K, et al. Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res. 1999;29:110-3. https://doi. org/10.1007/s005990050073 PMid:10592107
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Israa M. Al-Bayaa, Haithem Ahmed Al-Rubaie, Haider Hasan Al-Shammari (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
